Diroximel fumarate – a new twist for MS agent best seller

Tarek Gaber

Found an issue? Give us feedback

Progress in Neurolog...arrow_drop_down

Progress in Neurology and Psychiatry

Article . 2022 . Peer-reviewed

License: Wiley Online Library User Agreement

Data sources: Crossref

Diroximel fumarate – a new twist for MS agent best seller

descriptionPublicationkeyboard_double_arrow_right Article 01 Jul 2022 English Publisher:WileyJournal:Progress in Neurology and Psychiatry, volume 26, pages 8-9 (issn: 1367-7543, eissn: 1931-227X,

Copyright policy )

Authors: Tarek Gaber;

doi: 10.1002/pnp.752

Diroximel fumarate – a new twist for MS agent best seller

- Summary
- Metrics

Abstract

Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 NICE used FTA to recommend diroximel fumarate (Vumerity) for the management of relapsing remitting multiple sclerosis (RRMS). This short article explores the potential role the drug may play within the pantheon of disease modifying treatment for RRMS.

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average